



REV. 04/01
For A Small Entity

600 16347208
Docket No. MPG-1 DIV1

Applicant(s) : Michael Wassenegger et al.
Application No. : 09/782,874
Confirmation No. : Not yet assigned
Filed : February 8, 2001
For : NUCLEIC ACID MOLECULES ENCODING
POLYPEPTIDES HAVING THE ENZYMATIC
ACTIVITY OF AN RNA-DIRECTED RNA
POLYMERASE (RdRP)
Group Art Unit : Not yet assigned
Examiner : Not yet assigned

RECEIVED
MAY 17 2001
TECH CENTER 1600/2900

Hon. Commissioner for Patents
Washington, D.C. 20231

New York, New York
May 8, 2001

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Supplemental
Preliminary Amendment; ☐ a Reply to Office Action; to be
filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

☐ A fee for additional claims is not required.

☒ A fee for additional claims is required.

RECEIVED

MAY 17 2001

The additional fee has been calculated as shown below. **TECH CENTER 1600/2900**

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	60	-	58	= 2 X \$ 9 = \$18.00
INDEPENDENT CLAIMS	2	-	1	= 1 X \$ 40 = \$40.00
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM				+ \$135 = \$
TOTAL				<u>\$58.00</u>

- ☒ [X] A check in the amount of \$ 58.00 in payment of the filing fee is transmitted herewith.
- ☒ [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.
- ☐ [] Please charge \$_____ to Deposit Account No. 06-1075 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

- ☐ [] The following extension is applicable to the Response filed herewith; ☐ [] \$55.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$195.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$445.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$695.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$945.00 extension fee for response within fifth month pursuant to 37 C.F.R. 1.136(a).
- ☐ [] A check in the amount of ☐ [] \$55.00; ☐ [] \$195.00; ☐ [] \$445.00; ☐ [] \$695.00; ☐ [] \$945.00; in payment of the extension fee is transmitted herewith.

- [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.
- [] Please charge the [] \$55.00; [] \$195.00; [] \$445.00; [] \$695.00; [] \$945.00; extension fee to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

James F. Haley

James F. Haley (Reg. No. 27,794)
Attorney for Applicants
Karen E. Brown (Reg. No. 43,866)
R. Minako Pazdera (Reg. No. 46,984)
Agents for Applicants
c/o Fish & Neave (Customer No. 1473)
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090

I hereby certify that this
correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on

May 8, 2001
CLARENCE J. SAINTEZ

[Signature]
Signature of Person Signing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned

Group : Not yet assigned

Applicants : Michael Wassenegger et al.

Application No. : 09/782,874

Confirmation No. : Not yet assigned

Filed : February 8, 2001

For : NUCLEIC ACID MOLECULES ENCODING
POLYPEPTIDES HAVING THE ENZYMATIC ACTIVITY
OF AN RNA-DIRECTED RNA POLYMERASE (RdRP)

New York, New York
May 8, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Prior to examining this application, kindly amend the application as follows:

IN THE CLAIMS

Please add claims 51 and 52 as follows:

B1

51. (Added) A method of using the nucleic acid molecule of claim 7, the vector of claim 8 or 9, the antibody of claim 15, and/or the antagonist/inhibitor of claim 16 to inhibit RNA-directed RNA polymerase activities.